CF
VRTX icon

Copperwynd Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Copperwynd Financial’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,556
Closed -$2.24M – 157
2024
Q4 		$2.24M Buy
5,556
+576
+12% +$267K 0.62% 33
2024
Q3 		$2.32M Buy
4,980
+474
+11% +$228K 0.7% 27
2024
Q2 		$2.23M Sell
4,506
-272
-6% -$118K 0.73% 25
2024
Q1 		$2M Buy
4,778
+262
+6% +$111K 0.72% 26
2023
Q4 		$1.84M Sell
4,516
-47
-1% -$17.4K 0.73% 24
2023
Q3 		$1.59M Sell
4,563
-48
-1% -$16.8K 0.74% 24
2023
Q2 		$1.62M Sell
4,611
-81
-2% -$27.3K 0.76% 30
2023
Q1 		$1.48M Buy
4,692
+3
+0.1% +$900 0.76% 32
2022
Q4 		$1.35M Buy
4,689
+166
+4% +$50.6K 0.76% 31
2022
Q3 		$1.31M Sell
4,523
-62
-1% -$17.8K 0.75% 28
2022
Q2 		$1.29M Buy
+4,585
New +$1.23M 0.76% 31

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Copperwynd Financial's VRTX Position: Q1 2025 in Review

Copperwynd Financial sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 5,556 shares — an estimated $2.24M sold.

Copperwynd Financial first reported a position in VRTX in Q2 2022 and held it in 11 quarters. The position peaked at $2.32M in Q3 2024. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Copperwynd Financial reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Copperwynd Financial sold 5,556 Vertex Pharmaceuticals shares in Q1 2025, an estimated $2.24M.
  • Copperwynd Financial first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Copperwynd Financial's Vertex Pharmaceuticals position peaked at $2.32M in Q3 2024.
  • 1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Copperwynd Financial's 13F filing for Q1 2025, filed 5 May 2025.